This study is completed. It focuses on bipolarity and currently lists study information in Japan and the United States.
This completed Phase 2 study tested whether the oral investigational medication ABBV-932 was safe and could improve depressive episodes in adults living with bipolarity type I or II. Participants were assigned to one of three ABBV-932 dose groups or to placebo, took capsules once daily for 6 weeks, and then had a 4-week safety follow-up.
The official record lists this AbbVie study as completed, with sites in the United States, Japan, and Puerto Rico. Participation involved oral capsules of ABBV-932 or placebo, weekly clinic visits during the 6-week treatment period, medical assessments, blood tests, side-effect checks, questionnaires, and a 4-week safety follow-up. The main fit was adults aged 18 to 65 with bipolarity type I or II, without psychotic features, who were in a current depressive episode and met the study's symptom-score requirements. Key exclusions included a positive urine drug screen, recent investigational drug use, current enrollment in another clinical study, recent use of psychoactive medication, and prior recent exposure to ABBV-932.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.
This study is sponsored by AbbVie. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is Phase 2. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. The planned or actual enrollment is 161 participants. Larger studies may provide more information about how the intervention performs across a wider group, but size alone does not prove that a study is right for you. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.